Literature DB >> 17405919

Signaling pathways involved in proteinase-activated receptor1-induced proinflammatory and profibrotic mediator release following lung injury.

Paul F Mercer1, Xiaoling Deng, Rachel C Chambers.   

Abstract

The proteinase-activated receptors (PAR1 to 4) represent important novel therapeutic targets in fibroproliferative lung disorders, linking signals from coagulation proteinases to the production of proinflammatory and profibrotic mediators, in response to lung injury. This review focuses on the current understanding of cytokine and chemokine release downstream of PAR1 activation in the context of fibroproliferative lung disease, with an emphasis on the induction of the chemokine CCL2/MCP-1.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17405919     DOI： 10.1196/annals.1397.073

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain.

Authors:  Hiroshi Shigetomi; Akira Onogi; Hirotaka Kajiwara; Shozo Yoshida; Naoto Furukawa; Shoji Haruta; Yasuhito Tanase; Seiji Kanayama; Taketoshi Noguchi; Yoshihiko Yamada; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Inflamm Res       Date:  2010-05-08       Impact factor: 4.575

Review 2.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

3.  Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Richard M Silver
Journal:  Arthritis Rheum       Date:  2009-11

4.  Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Paul J Nietert; Tanjina Akter; Joanne van Ryn; Richard M Silver
Journal:  Arthritis Rheum       Date:  2011-05

Review 5.  Coagulation and autoimmunity in scleroderma interstitial lung disease.

Authors:  Anna Ludwicka-Bradley; Richard M Silver; Galina S Bogatkevich
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

6.  Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.

Authors:  Vladislava O Melnikova; Krishnakumar Balasubramanian; Gabriel J Villares; Andrey S Dobroff; Maya Zigler; Hua Wang; Frederik Petersson; Janet E Price; Alan Schroit; Victor G Prieto; Mien-Chie Hung; Menashe Bar-Eli
Journal:  J Biol Chem       Date:  2009-08-24       Impact factor: 5.157

7.  PAR1 contributes to influenza A virus pathogenicity in mice.

Authors:  Khaled Khoufache; Fatma Berri; Wolfgang Nacken; Annette B Vogel; Marie Delenne; Eric Camerer; Shaun R Coughlin; Peter Carmeliet; Bruno Lina; Guus F Rimmelzwaan; Oliver Planz; Stephan Ludwig; Béatrice Riteau
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

8.  PAR1 activation induces rapid changes in glutamate uptake and astrocyte morphology.

Authors:  Amanda M Sweeney; Kelsey E Fleming; John P McCauley; Marvin F Rodriguez; Elliot T Martin; Alioscka A Sousa; Richard D Leapman; Annalisa Scimemi
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

9.  Protease-activated receptor-1: key player in the sepsis coagulation-inflammation crosstalk.

Authors:  Karim Asehnoune; Pierre Moine
Journal:  Crit Care       Date:  2013-02-26       Impact factor: 9.097

10.  Integration of Genome-Wide DNA Methylation and Transcription Uncovered Aberrant Methylation-Regulated Genes and Pathways in the Peripheral Blood Mononuclear Cells of Systemic Sclerosis.

Authors:  Honglin Zhu; Chengsong Zhu; Wentao Mi; Tao Chen; Hongjun Zhao; Xiaoxia Zuo; Hui Luo; Quan-Zhen Li
Journal:  Int J Rheumatol       Date:  2018-09-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.